In the case of Amicus Therapeutics Inc. (NASDAQ: FOLD), what’s next?

Amicus Therapeutics Inc. (NASDAQ: FOLD) closed the day trading at 10.86 up 2.65% from the previous closing price of $10.58. In other words, the price has increased by $+0.28 from its previous closing price. On the day, 4822661 shares were traded. FOLD reached its highest trading level at $11.12 during the session, while it also had its lowest trading level at $10.41.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .



For a better understanding of FOLD, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.90 and its Current Ratio is at 3.00. In the meantime, Its Debt-to-Equity ratio is 2.25 whereas as Long-Term Debt/Eq ratio is at 2.25.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Morgan Stanley on September 09, 2022, initiated with a Equal-Weight rating and assigned the stock a target price of $14.

SVB Leerink Upgraded its Mkt Perform to Outperform on January 14, 2022, whereas the target price for the stock was revised from $12 to $16.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 15 when Crowley John F sold 10,468 shares for $10.66 per share. The transaction valued at 111,628 led to the insider holds 856,897 shares of the business.

Campbell Bradley L sold 5,470 shares of FOLD for $61,764 on Sep 01. The President & CEO now owns 689,618 shares after completing the transaction at $11.29 per share. On Sep 01, another insider, Quimi Daphne, who serves as the Chief Financial Officer of the company, sold 4,397 shares for $11.29 each. As a result, the insider received 49,621 and left with 335,312 shares of the company.

Valuation Measures:

For the stock, the TTM Price-to-Sale (P/S) ratio is 9.78 while its Price-to-Book (P/B) ratio in mrq is 18.41.

Stock Price History:

Over the past 52 weeks, FOLD has reached a high of $12.96, while it has fallen to a 52-week low of $5.91. The 50-Day Moving Average of the stock is 11.28, while the 200-Day Moving Average is calculated to be 9.73.

Shares Statistics:

Over the past 3-months, FOLD traded about 3.15M shares per day on average, while over the past 10 days, FOLD traded about 3.29M shares per day. A total of 291.97M shares are outstanding, with a floating share count of 251.87M. Shares short for FOLD as of Jul 14, 2022 were 21.75M with a Short Ratio of 6.87, compared to 29.93M on Jun 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 7.76% and a Short% of Float of 7.81%.

Earnings Estimates

Current recommendations for the stock of the company come from 10 analysts. On average, analysts expect EPS of $-0.22 for the current quarter, with a high estimate of $-0.15 and a low estimate of $-0.29, while EPS last year was $-0.19. The consensus estimate for the next quarter is $-0.19, with high estimates of $-0.14 and low estimates of $-0.24.

Analysts are recommending an EPS of between $-0.67 and $-1.01 for the fiscal current year, implying an average EPS of $-0.88. EPS for the following year is $-0.14, with 11 analysts recommending between $0.06 and $-0.37.

Revenue Estimates

11 analysts predict $85.89M in revenue for the current quarter. It ranges from a high estimate of $90.33M to a low estimate of $81.22M. As of the current estimate, Amicus Therapeutics Inc.’s year-ago sales were $73.39M, an estimated increase of 17.00% from the year-ago figure. For the next quarter, 11 analysts are estimating revenue of $90.7M, an increase of 14.00% less than the figure of $17.00% in the same quarter last year. There is a high estimate of $94.8M for the next quarter, whereas the lowest estimate is $86M.

A total of 12 analysts have provided revenue estimates for FOLD’s current fiscal year. The highest revenue estimate was $367.75M, while the lowest revenue estimate was $336.93M, resulting in an average revenue estimate of $355.01M. In the same quarter a year ago, actual revenue was $305.51M, up 16.20% from the average estimate. Based on 12 analysts’ estimates, the company’s revenue will be $489.34M in the next fiscal year. The high estimate is $565M and the low estimate is $431.6M. The average revenue growth estimate for next year is up 37.80% from the average revenue estimate for this year.